PDLIM7 and neoplasm: Scheme 1 illustrates a predicted in vivo scenario of how the new nanoplatform can be delivered from the tumor microenvironment, enter an EBV‐positive cell via the cell surface LMP1 protein, penetrate into the cell nucleus and target EBNA1.